PubRank

Hans-Peter Sinn

Author PubWeight™ 42.55‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 2011 3.37
2 Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2011 2.72
3 A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 2012 2.45
4 International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003 1.83
5 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res 2012 1.81
6 Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res 2005 1.77
7 Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res 2011 1.65
8 Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006 1.41
9 Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 2008 1.31
10 Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 2009 1.07
11 Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med (Berl) 2009 1.03
12 Breast cancer in young women (< or = 35 years): Genomic aberrations detected by comparative genomic hybridization. Int J Cancer 2003 1.02
13 The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer 2005 1.00
14 Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int J Cancer 2003 1.00
15 Triple-Negative Breast Cancer: Clinical and Histological Correlations. Breast Care (Basel) 2011 1.00
16 Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J 2012 0.99
17 Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs 2007 0.99
18 Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression. Int J Cancer 2003 0.99
19 Circulating fibronectin controls tumor growth. Neoplasia 2013 0.92
20 Automatic tumor-stroma separation in fluorescence TMAs enables the quantitative high-throughput analysis of multiple cancer biomarkers. PLoS One 2011 0.89
21 P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer 2002 0.88
22 Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. Breast 2013 0.87
23 Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. Cancer 2002 0.84
24 Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression. Oncology 2002 0.84
25 Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. Med Sci Monit 2009 0.82
26 Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy. Anticancer Drugs 2004 0.81
27 Intraoperative venous blood sampling to localize a small androgen-producing ovarian tumor. Gynecol Endocrinol 2005 0.80
28 Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany. Eur J Hum Genet 2003 0.80
29 Predictors of resectability in breast-conserving therapy. Arch Gynecol Obstet 2012 0.80
30 Differentiation and histogenesis of syringomatous tumour of the nipple and low-grade adenosquamous carcinoma: evidence for a common origin. Histopathology 2014 0.79
31 Omission of axillary dissection according to ACOSOG Z0011: impact on adjuvant treatment recommendations. Ann Surg Oncol 2013 0.79
32 Breast cancer precursors: lessons learned from molecular genetics. J Mol Med (Berl) 2009 0.79
33 Comparison of immunohistological parameters in primary breast cancers and corresponding locoregional recurrences. Pathol Res Pract 2006 0.77
34 Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk. Arch Gynecol Obstet 2013 0.77
35 Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα-positive breast cancer. Int J Cancer 2012 0.76
36 Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients. Cancer Immunol Immunother 2010 0.76
37 Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial. Anticancer Drugs 2005 0.76
38 Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families. Hered Cancer Clin Pract 2004 0.75
39 Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial. Clin Breast Cancer 2007 0.75
40 Giant struma ovarii. Arch Gynecol Obstet 2012 0.75
41 Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support. Stem Cells 2002 0.75
42 Vacuum-Assisted Biopsy to Diagnose a Pathological Complete Response in Breast Cancer Patients After Neoadjuvant Systemic Therapy. Ann Surg 2017 0.75